Literature DB >> 20048685

Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency.

Chia-Yang Hsu1, Yi-Hsiang Huang, Chien-Wei Su, Jen-Huey Chiang, Han-Chieh Lin, Pui-Ching Lee, Fa-Yauh Lee, Teh-Ia Huo, Shou-Dong Lee.   

Abstract

BACKGROUND: Renal dysfunction is often present in patients with cirrhosis and hepatocellular carcinoma (HCC). Acute renal failure (ARF) may occur after transarterial chemoembolization (TACE) owing to radiocontrast agent. This study investigated the incidence and risk factors of ARF and prognostic predictors in HCC patients with preexisting renal insufficiency undergoing TACE.
METHODS: A total of 566 HCC patients undergoing TACE were enrolled. Renal insufficiency was defined as an estimated glomerular filtration rate less than 60 mL/min/1.73 m.
RESULTS: In a mean follow-up duration of 18+/-16 months, 231 (40.8%) patients undergoing TACE died. Renal insufficiency that was present in 134 (23.7%) patients at baseline, independently predicted a poor prognosis in the Cox proportional hazards model [risk ratio (RR): 1.47, P=0.012]. Of them, 13 (10%) and 6 (5%) patients had transient and prolonged ARF after TACE, respectively. Post-TACE gastrointestinal bleeding [odds ratio (OR): 16.54, P=0.001] and higher Cancer of the Liver Italian Program (CLIP) scores (> or =2; OR: 4.22, P=0.02) were independent risk factors for ARF in the multivariate logistic regression analysis. In the Cox model, prolonged ARF (RR: 3.28, P<0.001) and higher CLIP scores (> or =2; RR: 2.13, P<0.001) were independent poor prognostic predictors for HCC patients with renal insufficiency receiving TACE.
CONCLUSIONS: Gastrointestinal bleeding and higher CLIP scores are associated with the development of ARF in patients with HCC and renal insufficiency undergoing TACE. Higher CLIP scores and renal insufficiency, either preexisting before TACE or as a complication of TACE, are poor prognostic predictors in HCC patients receiving TACE.

Entities:  

Mesh:

Year:  2010        PMID: 20048685     DOI: 10.1097/MCG.0b013e3181c88235

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  13 in total

1.  Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort.

Authors:  Pei-Hsuan Weng; Kuan-Yu Hung; Hsien-Liang Huang; Jen-Hau Chen; Pei-Kun Sung; Kuo-Chin Huang
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 8.237

2.  Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.

Authors:  Mari Aoe; Takafumi Kanemitsu; Takamasa Ohki; Satoru Kishi; Yoshiyasu Ogura; Yuto Takenaka; Toyohiro Hashiba; Hiroko Ambe; Emi Furukawa; Yu Kurata; Masahiro Ichikawa; Ken Ohara; Tomoko Honda; Satoshi Furuse; Katsunori Saito; Nobuo Toda; Naobumi Mise
Journal:  Clin Exp Nephrol       Date:  2019-06-10       Impact factor: 2.801

3.  Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Ya-Ju Tsai; Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Rheun-Chuan Lee; Jen-Huey Chiang; Teh-Ia Huo; Shou-Dong Lee
Journal:  Hepatol Int       Date:  2011-04-30       Impact factor: 6.047

4.  Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy.

Authors:  Chia-Yang Hsu; Yun-Hsuan Lee; Yi-Hsiang Huang; Cheng-Yuan Hsia; Chien-Wei Su; Han-Chieh Lin; Rheun-Chuan Lee; Yi-You Chiou; Fa-Yauh Lee; Teh-Ia Huo; Shou-Dong Lee
Journal:  Hepatol Int       Date:  2012-01-08       Impact factor: 6.047

5.  The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC).

Authors:  Katsumi Hayakawa; Masato Tanikake; Toshihiko Kirishima; Naomi Yoshinami; Hiroyuki Shintani; Eiji Yamamoto; Taisuke Morimoto
Journal:  Eur Radiol       Date:  2014-02-13       Impact factor: 5.315

6.  Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Chunze Zhou; Ruifeng Wang; Yikun Ding; Linan Du; Changlong Hou; Dong Lu; Li Hao; Weifu Lv
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

7.  Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma.

Authors:  Matan J Cohen; Allan I Bloom; Orly Barak; Alexander Klimov; Tova Nesher; Daniel Shouval; Izhar Levi; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

8.  Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade.

Authors:  Chih-Chieh Ko; Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Hao-Jan Lei; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  Int J Clin Oncol       Date:  2022-02-04       Impact factor: 3.402

9.  A New Treatment-integrated Prognostic Nomogram of the Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma.

Authors:  Chia-Yang Hsu; Po-Hong Liu; Cheng-Yuan Hsia; Yun-Hsuan Lee; Teddy S Nagaria; Rheun-Chuan Lee; Shu-Yein Ho; Ming-Chih Hou; Teh-Ia Huo
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

10.  350-560 μm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: The safety and efficacy.

Authors:  Guang Sheng Zhao; Chuang Li; Ying Liu; Zhi Zhong Ren; Xiao Lin Yuan; Jun Zhou; Yue Wei Zhang; Ming Zhang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.